Original Articles Paroxysmal Non-Epileptic Movements in Childhood
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pyrexia of Unknown Origin. Presenting Sign of Hypothalamic Hypopituitarism R
Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from Postgraduate Medical Journal (May 1981) 57, 310-313 Pyrexia of unknown origin. Presenting sign of hypothalamic hypopituitarism R. MARILUS* A. BARKAN* M.D. M.D. S. LEIBAt R. ARIE* M.D. M.D. I. BLUM* M.D. *Department of Internal Medicine 'B' and tDepartment ofEndocrinology, Beilinson Medical Center, Petah Tiqva, The Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel Summary least 10 such admissions because offever of unknown A 62-year-old man was admitted to hospital 10 times origin had been recorded. During this period, he over 12 years because of pyrexia of unknown origin. was extensively investigated for possible infectious, Hypothalamic hypopituitarism was diagnosed by neoplastic, inflammatory and collagen diseases, but dynamic tests including clomiphene, LRH, TRH and the various tests failed to reveal the cause of theby copyright. chlorpromazine stimulation. Lack of ACTH was fever. demonstrated by long and short tetracosactrin tests. A detailed past history of the patient was non- The aetiology of the disorder was believed to be contributory. However, further questioning at a previous encephalitis. later period of his admission revealed interesting Following substitution therapy with adrenal and pertinent facts. Twelve years before the present gonadal steroids there were no further episodes of admission his body hair and sex activity had been fever. normal. At that time he had an acute febrile illness with severe headache which lasted for about one Introduction week. He was not admitted to hospital and did not http://pmj.bmj.com/ Pyrexia of unknown origin (PUO) may present receive any specific therapy. -
Research Experiences Research Is an Important Part of the Training of Child Neurology Residents at Children’S Mercy Hospital
Research Experiences Research is an important part of the training of Child Neurology residents at Children’s Mercy Hospital. Training in research starts with the research mentor that each resident is encouraged to engage at the beginning of their child neurology training. The residents are also invited to complete a course on biostatistics and each resident is expected to complete a 1 year course in Quality Improvement and Clinical Safety. As part of the QI course each resident will initiate a QI project which can be presented at CMH Research Day. Each resident is also given the opportunity to present at the yearly Missouri Valley Child Neurology Colloquium. This is a joint meeting with The University of Washington and Saint Louis University Child Neurology programs. Finally, each resident is expected to graduate with at least one first author publication. Over the last 4 years our residents have given over 100 talks (with approximately 20% of these original research or case presentations) and have published 13 papers in peer reviewed journals (including original research and review papers). Faculty Program Director Jean-Baptiste (J.B.) Le Pichon, MD, PhD: Dr. Le Pichon was born in New York City but grew up in France. He completed his undergraduate education at Gannon University, Erie Pennsylvania followed by an MD/PhD program at Baylor College of Medicine, Houston Texas. Dr. Le Pichon completed his PhD in neuroscience. Following medical school, he completed two years of Pediatrics at Driscoll Children’s Hospital in Corpus Christi and then completed a Child Neurology Residency at Texas Children’s Hospital. -
Myoclonus Aspen Summer 2020
Hallett Myoclonus Aspen Summer 2020 Myoclonus (Chapter 20) Aspen 2020 1 Myoclonus: Definition Quick muscle jerks Either irregular or rhythmic, but always simple 2 1 Hallett Myoclonus Aspen Summer 2020 Myoclonus • Spontaneous • Action myoclonus: activated or accentuated by voluntary movement • Reflex myoclonus: activated or accentuated by sensory stimulation 3 Myoclonus • Focal: involving only few adjacent muscles • Generalized: involving most or many of the muscles of the body • Multifocal: involving many muscles, but in different jerks 4 2 Hallett Myoclonus Aspen Summer 2020 Differential diagnosis of myoclonus • Simple tics • Some components of chorea • Tremor • Peripheral disorders – Fasciculation – Myokymia – Hemifacial spasm 9 Classification of Myoclonus Site of Origin • Cortex – Cortical myoclonus, epilepsia partialis continua, cortical tremor • Brainstem – Reticular myoclonus, exaggerated startle, palatal myoclonus • Spinal cord – Segmental, propriospinal • Peripheral – Rare, likely due to secondary CNS changes 10 3 Hallett Myoclonus Aspen Summer 2020 Classification of myoclonus to guide therapy • First consideration: Etiological classification – Is there a metabolic encephalopathy to be treated? Is there a tumor to be removed? Is a drug responsible? • Second consideration: Physiological classification – Can the myoclonus be treated symptomatically even if the underlying condition remains unchanged? 12 Myoclonus: Physiological Classification • Epileptic • Non‐epileptic The basic question to ask is whether the myoclonus is a “fragment -
Hypothalamic Hamartoma
Neurol Med Chir (Tokyo) 45, 221¿231, 2005 Hypothalamic Hamartoma Kazunori ARITA,KaoruKURISU, Yoshihiro KIURA,KojiIIDA*, and Hiroshi OTSUBO* Department of Neurosurgery, Graduate School of Biomedical Science, Hiroshima University, Hiroshima; *Division of Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada Abstract The incidence of hypothalamic hamartomas (HHs) has increased since the introduction of magnetic resonance (MR) imaging. The etiology of this anomaly and the pathogenesis of its peculiar symptoms remain unclear, but recent electrophysiological, neuroimaging, and clinical studies have yielded important data. Categorizing HHs by the degree of hypothalamic involvement has contributed to the accurate prediction of their prognosis and to improved treatment strategies. Rather than undergoing corticectomy, HH patients with medically intractable seizures are now treated with surgery that targets the HH per se, e.g. HH removal, disconnection from the hypothalamus, stereotactic irradiation, and radiofrequency lesioning. Although surgical intervention carries risks, total eradication or disconnec- tion of the lesion leads to cessation or reduction of seizures and improves the cognitive and behavioral status of these patients. Precocious puberty in HH patients is safely controlled by long-acting gonadotropin-releasing hormone agonists. The accumulation of knowledge regarding the pathogenesis of symptoms and the development of safe, effective treatment modalities may lead to earlier interven- tion in young HH patients and prevent -
Pediatric Neuro-Ophthalmology
Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky, M.D. Professor of Ophthalmology and Neurology Mayo Clinic Rochester, Minnesota USA ISBN 978-0-387-69066-7 e-ISBN 978-0-387-69069-8 DOI 10.1007/978-0-387-69069-8 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010922363 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connec-tion with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with re-spect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) To the good angels in my life, past and present, who lifted me on their wings and carried me through the storms. -
NEUROLOGY in TABLE.Pdf
ZAPORIZHZHIA STATE MEDICAL UNIVERSITY DEPARTMENT OF NEUROLOGY DISEASES NEUROLOGY IN TABLE (General neurology) for practical employments to the students of the IV course of medical faculty Zaporizhzhia, 2015 2 It is approved on meeting of the Central methodical advice Zaporozhye state medical university (the protocol № 6, 20.05.2015) and is recommended for use in scholastic process. Authors: doctor of the medical sciences, professor Kozyolkin O.A. candidate of the medical sciences, assistant professor Vizir I.V. candidate of the medical sciences, assistant professor Sikorskaya M.V. Kozyolkin O. A. Neurology in table (General neurology) : for practical employments to the students of the IV course of medical faculty / O. A. Kozyolkin, I. V. Vizir, M. V. Sikorskaya. – Zaporizhzhia : [ZSMU], 2015. – 94 p. 3 CONTENTS 1. Sensitive function …………………………………………………………………….4 2. Reflex-motor function of the nervous system. Syndromes of movement disorders ……………………………………………………………………………….10 3. The extrapyramidal system and syndromes of its lesion …………………………...21 4. The cerebellum and it’s pathology ………………………………………………….27 5. Pathology of vegetative nervous system ……………………………………………34 6. Cranial nerves and syndromes of its lesion …………………………………………44 7. The brain cortex. Disturbances of higher cerebral function ………………………..65 8. Disturbances of consciousness ……………………………………………………...71 9. Cerebrospinal fluid. Meningealand hypertensive syndromes ………………………75 10. Additional methods in neurology ………………………………………………….82 STUDY DESING PATIENT BY A PHYSICIAN NEUROLOGIST -
Diencephalic Syndrome: a Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance
Diencephalic Syndrome: A Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance Amy Fleischman, MD*; Catherine Brue, MD*; Tina Young Poussaint, MD‡; Mark Kieran, MD, PhD§; Scott L. Pomeroy, MD, PhD¶; Liliana Goumnerova, MD#; R. Michael Scott, MD#; and Laurie E. Cohen, MD* ABSTRACT. Diencephalic syndrome is a rare but po- total of 48 similar cases, including the 12 described tentially lethal cause of failure to thrive in infants and by Russell. Since then, several case studies have been young children. The diencephalic syndrome includes reported with similar symptoms, a few with brain clinical characteristics of severe emaciation, normal lin- tumors located in the posterior fossa.2,3 Nystagmus ear growth, and normal or precocious intellectual devel- and vomiting were also noted in the majority of opment in association with central nervous system tu- reported cases.2–5 In 1976, a review of 72 cases by mors. Our group initially described a series of 9 patients 6 with diencephalic syndrome and found a reduced prev- Burr confirmed the clinical characteristics of dience- alence of emesis, hyperalertness, or hyperactivity com- phalic syndrome. Subsequent literature has consisted pared with previous reports. Also, the tumors were found of multiple case series and case reports of this to be larger, occur at a younger age, and behave more syndrome. aggressively than similarly located tumors without dien- We reviewed the 11 cases of diencephalic syn- cephalic syndrome. We have been able to extend our drome that presented to Children’s Hospital Boston follow-up of the original patients, as well as describe 2 and Dana-Farber Cancer Institute between 1970 and additional cases. -
Acoustic Neurinoma. See Vestibular Schwannomas Acquired
3601_e28index_p591-606 2/19/02 9:09 AM Page 591 Index Page numbers followed by “f” indicate figures; numbers followed by “t” indicate tables; “CF” indicates color figures. Acoustic neurinoma. See Vestibular schwannomas Amenorrhea-galactorrhea syndrome, 168 Acquired immunodeficiency disease (AIDS) Amifostine and neuroprotection, 407 lymphomatous meningitis and, 376 Amputation and cancer pain, 506–7 Acromegaly, 210 Amyloid neuropathy, 402 Acroparesthesia, 398 Analgesics. See also Cancer pain Acute radiation syndrome, 574–75 adjuvant drugs, 517t–518t, 524–25 Addiction and opioid analgesics, 523 nonopioid, 510–11, 510t Adenocarcinoma of anterior skull base, 316 opioid. See Opioid analgesics Adenohypophysis, 208. See also Pituitary tumors Anemia and behavioral changes, 560 Adenoid cystic carcinoma of anterior skull base, 316 Aneurysms, neoplastic, 457 Adenoma sebaceum and tuberous sclerosis, 96 Angiography, cerebral, 282–84, 283f Adenomas. See also Pituitary tumors Angiomas, cavernous, 20–21 imaging, 11, 14f Antibodies and paraneoplastic neurologic disease, 424, 425t Adjustment disorders, 578–79. See also Psychological issues Anticonvulsants, 576. See also Seizure, treatment for cancer pain, prevalence, 573 524–25 Adjuvant drugs. See also specific medications neurobehavioral changes, 560 adverse effects of, 559–60 Antidepressants, 579–81, 579t analgesic, 517t–518t, 524–25 Antiemetics Adrenal dysfunction after cancer treatment, 540 and seizures, 441 Adrenocorticotropin (ACTH) and syncope, 448 after cancer treatment, 538 Antihistamines and brain -
Opsoclonus-Myoclonus Presenting with Features of Spasmus Nutans
67 References scans of the brain were normal, and cerebrospinal fluid was acellular, 1. Balk R, Hiller C, Lucas EA, et al: Sleep apnea and the Arnold Chiari with normal chemistries. A 24-hour urine collection revealed vanilmandel- malformation. Am Rev Respir Dis 1985;132:929-930. ic acid, 1.9 mg/total volume (normal, 1 to 1.5 mg); homovanillic acid, 1.4 2. Ruff ME, Oakes WJ, Fisher SR, Spock A: Sleep apnea and vocal mg/total volume (normal, 0 to 4 mg); homovanillic acid/creatinine ratio, cord paralysis secondary to type I Chiari malformation. Pediatrics 17 mg/g of creatinine (normal, < 35 mg/g); epinephrine, 7.0 ug/tota.l volume 1987;80:231-234. (normal, 0 to 5.0 ug); and norepinephrine, 8.0 ug/total volume (normal, 0 3. Levitt P, Cohen MA: Sleep apnea and the Chiari I malformation: to 20 ug). Chest and abdominal computed tomographic and radiolabeled Case report. Neurosurgery 1988;23:508-510. metaiodobenzylguanidine scan did not show neuroblastoma. 4. Langevin B, Sukkar F, Leger P, et al: Sleep apnea syndromes (SAS) The child’s head tremor worsened over the ensuing 2 weeks to the of specific etiology: Review and incidence from a sleep laboratory. point of interfering with her sleep. Her parents now noted large involun- Sleep 1992;15:S25-S32. tary eye movements, increasing unsteadiness, and rapid jerking of the 5. White DP: Central sleep apnea, in Kryger MH, Roth T, Dement WC extremities that interrupted her attempts at feeding. Examination (eds): Principles and Practice of Sleep Medicine. Philadelphia, WB showed rapid, continuous horizontal, vertical, and oblique conjugate eye Saunders, 1989, pp 513-524. -
Indian Journal of Practical
INDIAN JOURNAL OF PRACTICAL PEDIATRICS • IJPP is a quarterly subscription journal of the Indian Academy of Pediatrics committed to presenting practical pediatric issues and management updates in a simple and clear manner • Indexed in Excerpta Medica, CABI Publishing, Scopus Vol.18 No.2 APR.- JUN. 2016 Dr.P.Ramachandran Dr.S.Thangavelu Editor-in-Chief Executive Editor CONTENTS TOPIC OF INTEREST - “PEDIATRIC NEUROLOGY” Approach to a child with acute flaccid paralysis 101 - Naveen Sankhyan, Renu Suthar Approach to a child with ataxia 109 - Leema Pauline C, Viveha Saravanan R, Ravi LA Pediatric CNS demyelinating disorders - An update 122 - Lokesh Lingappa, Nikit Milind Shah, Approach to muscle disorders in childhood 136 - Viswanathan V Hydrocephalus 144 - Hari VS, Thiagarajan G, Lakshmi Tilak S Epileptic encephalopathies in children 151 - Vinayan KP Neurometabolic disorders: A diagnostic approach 158 - Bindu PS, Arun B Taly Traumatic brain injury 171 - Soonu Udani Hypoxic ischemic encephalopathy in children: An intensivist’s perspective 180 - Jayashree M, Abhijit Choudhary Childhood migraine 186 - Sangeetha Yoganathan Journal Office and address for communications: Dr. P.Ramachandran, Editor-in-Chief, Indian Journal of Practical Pediatrics, 1A, Block II, Krsna Apartments, 50, Halls Road, Egmore, Chennai - 600 008. Tamil Nadu, India. Tel.No. : 044-28190032 E.mail : [email protected] 1 Indian Journal of Practical Pediatrics 2016;18(2) : 98 GENERAL ARTICLE Unexpected difficult pediatric airway:Pearls and pitfalls for the ED physician 193 -
Autoimmune Disorders and Paraneoplastic Syndromes in Thymoma
7590 Review Article on Thymoma Autoimmune disorders and paraneoplastic syndromes in thymoma Torsten Gerriet Blum, Daniel Misch, Jens Kollmeier, Sebastian Thiel, Torsten T. Bauer Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany Contributions: (I) Conception and design: TG Blum; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: TG Blum; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: TG Blum; (VII) Final approval of manuscript: All authors. Correspondence to: Dr. Torsten Gerriet Blum. Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Walterhöferstr. 11, 14165 Berlin, Germany. Email: [email protected]. Abstract: Thymomas are counted among the rare tumour entities which are associated with autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other malignancies. Through its complex immunological function in the context of the selection and maturation of T cells, the thymus is at the same time highly susceptible to disruptive factors caused by the development and growth of thymic tumours. These T cells, which are thought to develop to competent immune cells in the thymus, can instead adopt autoreactive behaviour due to the uncontrolled interplay of thymomas and become the trigger for AID or PNS affecting numerous organs and tissues within the human body. While myasthenia gravis is the most prevalent PNS in thymoma, numerous others have been described, be they related to neurological, cardiovascular, gastrointestinal, haematological, dermatological, endocrine or systemic disorders. This review article sheds light on the pathophysiology, epidemiology, specific clinical features and therapeutic options of the various forms as well as courses and outcomes of AID/PNS in association with thymomas. -
Biomarkers in Rare Demyelinating Disease of the Central Nervous System
International Journal of Molecular Sciences Review Biomarkers in Rare Demyelinating Disease of the Central Nervous System Marina Boziki , Styliani-Aggeliki Sintila, Panagiotis Ioannidis and Nikolaos Grigoriadis * 2nd Neurological University Department, Aristotle University of Thessaloniki, AHEPA General Hospital, 54634 Thessaloniki, Greece; [email protected] (M.B.); [email protected] (S.-A.S.); [email protected] (P.I.) * Correspondence: [email protected]; Tel.: +30-2310994683 Received: 14 October 2020; Accepted: 7 November 2020; Published: 9 November 2020 Abstract: Rare neurological diseases are a heterogeneous group corresponding approximately to 50% of all rare diseases. Neurologists are among the main specialists involved in their diagnostic investigation. At the moment, a consensus guideline on which neurologists may base clinical suspicion is not available. Moreover, neurologists need guidance with respect to screening investigations that may be performed. In this respect, biomarker research has emerged as a particularly active field due to its potential applications in clinical practice. With respect to autoimmune demyelinating diseases of the Central Nervous System (CNS), although these diseases occur in the frame of organ-specific autoimmunity, pathology of the disease itself is orchestrated among several anatomical and functional compartments. The differential diagnosis is broad and includes, but is not limited to, rare neurological diseases. Multiple Sclerosis (MS) needs to be differentially diagnosed from rare MS variants, Acute Disseminated Encephalomyelitis (ADEM), the range of Neuromyelitis Optica Spectrum Disorders (NMOSDs), Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease and other systemic inflammatory diseases. Diagnostic biomarkers may facilitate timely diagnosis and proper disease management, preventing disease exacerbation due to misdiagnosis and false treatment. In this review, we will describe advances in biomarker research with respect to rare neuroinflammatory disease of the CNS.